Journal of Clinical Neuroscience xxx (xxxx) xxx
Contents lists available at ScienceDirect
Journal of Clinical Neuroscience
journal homepage: www.elsevier.com/locate/jocn
Clinical study
Association of MIF and MBL2 gene polymorphisms with attempted
suicide in patients diagnosed with schizophrenia or bipolar disorder
Hasan Mervan Aytac a,1,⇑, Yasemin Oyaci c,2, Menekse Sila Yazar b,3, Ayse Erol c,4, Sacide Pehlivan c,5
a
Psychiatry Unit, Malazgirt State Hospital, Mus, Turkey
Department of Psychiatry, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey
c
Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Turkey
b
a r t i c l e
i n f o
Article history:
Received 8 February 2020
Accepted 3 April 2020
Available online xxxx
Keywords:
Schizophrenia
Bipolar disorder
Inflammation
MIF
MBL2
Attempted suicide
a b s t r a c t
The aim of this study to investigate the genetic polymorphisms in macrophage inhibitory factor (MIF) and
mannose-binding lectin 2 (MBL2) gene in schizophrenia (SCZ) or bipolar disorder (BD) patients with
attempted suicide by comparing with a non-attempted SCZ or BD patients and healthy controls. A sample
of 108 patients with SCZ, 100 patients with BD and 100 healthy volunteers were included in the study.
SCID-I was used to confirm the diagnosis according to DSM-IV-TR criteria. The patients were evaluated
by data forms that included sociodemographic, suicidal behavior and symptom severity information.
PCR-RFLP was used to determine MIF and MBL2 gene polymorphisms from DNA material. Our results
demonstrated that the distributions of MBL2 genotype (AA, AB, BB), combined genotype (AA, AB/BB)
and the allele frequencies (A, B) of attempted suicide patients in SCZ were statistically significantly different from the non-attempted SCZ patients. The distributions of the MBL2 genotype (-AA, AB, BB) of
attempted suicide patients in SCZ were statistically significantly different from the control group. The distributions of MIF genotype (GG, GC, CC), combined genotype (GG, GC/CC) and the allele frequencies (G, C)
of attempted suicide patients in BD were statistically significantly different from the non-attempted BD
patients or control group. In summary MBL2 gene polymorphism may be associated with attempted suicide in SCZ and MIF gene polymorphism might be associated with attempted suicide in BD. However, further studies with other gene variants in different ethnic populations are needed to address the exact role
of these polymorphisms in SCZ or BD.
Ó 2020 Elsevier Ltd. All rights reserved.
1. Introduction
Schizophrenia (SCZ) is a severe psychiatric disorder that can
cause significant impairments in psychosocial function, have a
chronic course and are seen in around 1% of the general population
[1]. The prevalence of lifetime suicide attempts in those with SCZ
ranges from 20% to 40%. It was estimated that one in every 20 individuals with SCZ will commit suicide [2]. Bipolar disorder (BD) is a
psychiatric disorder which is characterized by manic, depressive
and mixed episodes, cause significant impairments in psychosocial
⇑ Corresponding author.
E-mail addresses:
[email protected] (H.M. Aytac),
[email protected] (Y. Oyaci),
[email protected] (M.S. Yazar),
[email protected]
(A. Erol),
[email protected] (S. Pehlivan).
1
ORCID: https://orcid.org/0000-0002-1053-6808.
2
ORCID: https://orcid.org/0000-0002-1338-0087.
3
ORCID: https://orcid.org/0000-0002-3452-545X.
4
ORCID: https://orcid.org/0000-0003-4454-4651.
5
ORCID: https://orcid.org/0000-0003-1272-5845.
and occupational function during episodes [3]. It has been estimated that the risk of suicide in patients with BD to be 20–30
times higher than the population [4]. Lifetime suicide attempts
and completed suicides are estimated to range from 25 to 50 %
and 8–19% in BD [5].
Epidemiological studies have reported that the risk for suicidal
behavior (SB) is heritable, with the currently about 40%. This heritability depends on two main factors. The first factor is an association with psychiatric disorders, the secondly SB is inherited
independently [6]. At the same time, a certain genetic predisposition has not been understood yet. Numerous meta-analyses of
case-control studies have shown a strong association of genetic
polymorphisms with SBs variants in solute carrier family 6
member 4 (SLC6A4) or 5-HTT gene-linked polymorphic region
(5-HTTLPR), catechol-O-methyltransferase (COMT) -rs4680,
tryptophan hydroxylase 1 (TPH1) -rs1800532-, brain-derived neurotrophic factor (BDNF) -rs6265- and its receptor (NTRK2) are also
promising candidates [7]. Besides, recent studies reported aberrant
cytokine levels in the blood, cerebrospinal fluid, and postmortem
https://doi.org/10.1016/j.jocn.2020.04.001
0967-5868/Ó 2020 Elsevier Ltd. All rights reserved.
Please cite this article as: H. M. Aytac, Y. Oyaci, M. S. Yazar et al., Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients
diagnosed with schizophrenia or bipolar disorder, Journal of Clinical Neuroscience, https://doi.org/10.1016/j.jocn.2020.04.001
2
H.M. Aytac et al. / Journal of Clinical Neuroscience xxx (xxxx) xxx
brain samples from suicidal completers. For instance, increased
blood levels of tumor necrosis factor (TNF-a) and interleukin 6
(IL-6) are associated with suicidal ideation and attempt [8]. Pandey
et al. published that post-mortem brain tissue from teenage suicide
victims had increased messenger ribonucleic acid (mRNA) and protein levels of TNF-a, IL-1b and IL-6 in certain cortical regions [9].
However, monitoring only cytokine levels of serum and cerebrospinal fluid (CSF) and disregarding the confounding factors
(presence of concomitant autoimmune disease, an infection during
the measurement of samples) can be misleading without considering the inflammation-related genes.
The Macrophage Inhibitory Factor (MIF) gene is localized to the
q11.23 region on chromosome 22. MIF is a cytokine that is responsible for both the innate and acquired immune response. It carries
the features of a strong proinflammatory cytokine and may lead to
a chronification of diseases [10]. MIF has also been shown to facilitate the deoxyribonucleic acid (DNA) damage response and cell
cycle regulation and is related with the hypothalamic–pituitary–
adrenal (HPA) axis [11]. Especially as a dysregulation of the HPA
axis is hypothesized to play an important pathophysiological role
in psychiatric disorders [12]. Again Mannose-binding lectin 2
(MBL2) is an acute-phase protein that plays an important role in
the innate immune response. MBL2 is the only collectin that activates the lectin pathway, which is a third pathway different from
the classical and alternative pathways of the complement system.
It binds to microorganisms, acts as an opsonin, facilitates phagocytosis and activates macrophages. MBL2 is encoded by the MBL2
gene, which consists of 4 exons in the q11.2-q21 region of the long
arm of chromosome 10 [13]. When the literature is reviewed, there
is no study examining the relationship between SB and MBL2 gene
variants. Again apart from a study examining the relationship
between completed suicide and MIF gene polymorphism in the
Japanese population [14], there is no study examining the relationship between attempted suicide and MIF gene variant in SCZ or BD.
Therefore to our knowledge, this is the first study that has examined the relationship between MIF and MBL2 gene variant and
attempted suicide in SCZ or BD. The aim of this study is to investigate the relationship between MIF gene and MBL2 gene variant and
attempted suicide patient diagnosed with SCZ or BD.
2. Methods
2.1. Patient Selection
A sample of 108 patients with SCZ, 100 patients with BD was
followed at Bakirkoy Mazhar Osman Mental Health and Neurology
Training and Research Hospital in the period of January-June 2018;
additionally, 100 healthy volunteers were included in the study,
which was designed as a case-control study. The study was
approved by the Local Committee of Bakirkoy Mazhar Osman Mental Health and Neurology Training and Research Hospital
(81/07.11.2017).
2.1.1. Diagnostic tools and scales
The participants were informed in detail about the purpose,
method and procedures of the study, and their written consent
was obtained. The interview was started by filling out data forms
that included sociodemographic and clinical information. At the
outpatient policlinic interview, it was asked whether they
attempted suicide. If they mentioned that attempted suicide, it
was learned which method they used. Afterward, the Structured
Clinical Interview for DSM-IV Axis-I Disorders (SCID-I) was used
to confirm the diagnosis according to DSM-IV-TR criteria, and the
presence of any psychiatric diagnosis as a basis for exclusion from
the study in the healthy control group [15,16]. The Young Mania
Rating Scale (YMRS) [17,18], the Hamilton Depression Rating Scale
(HAM-D) [19,20] were administered to patients with BD to evaluate the severity of manic or depressive symptoms, to measure of
positive symptoms, negative symptoms and general psychopathology in psychotic patients the Positive and Negative Symptoms
Scale (PANSS) [21,22] were administered to patients with SCZ.
2.2. DNA isolation and genotyping analyses
Blood samples were obtained from participants at the Istanbul
Faculty of Medicine Laboratory of Medical Biology to isolate their
deoxyribonucleic acid (DNA) material using the GeneMark Plus
Blood Genomic DNA Purification Kit. Polymerase chain reaction
(PCR) and restriction fragment length polymorphism (RFLP) were
used to determine codon 54 A/B (gly54asp) variation in exon 1 of
the MBL2 gene and MIF gene
173 G/C polymorphism [23]. 10%
of the sample was randomly selected and the method was controlled on this sample.
2.3. Statistical analyses
Statistical analysis was performed using IBM SPSS version 21.0
(IBM Corp. released 2012; Armonk, NY, USA). Descriptive statistics
included mean, standard deviation, median, minimum, maximum,
frequency, percentage. Pearson chi-square test or Fisher’s exact
test was used to comparing discrete variables, and Bonferroni correction was used in pairwise comparisons to determine which
group or groups showed statistically significant results. Statistical
significance was accepted as p < 0.05 for the results of all analyses.
3. Results
When we look at the percentages of SB, 32.4% (n:35) of the SCZ
patients (n = 108; 27 female/81 male) and 30% (n:30) of the BD
patients (n = 100; 60 female/40 male) have attempted suicide.
The method and type of SB were evaluated on Table 1. The scale
scores of the patients diagnosed with SCZ or BD are shown on
Table 2.
When the MBL2 (AA, AB, BB) genotype, combined genotype
(grouping by considering the presence of mutation allele) (AA,
AB/BB) (homozygosis normal, heterozygosis/homozygosis mutant)
and the allele frequencies (A, B) of attempted suicide patients with
SCZ were compared with the non-attempted SCZ patients, the
MBL2 (AA, AB, BB) genotype (p = 0.026), (AA, AB/BB) combined
genotype (p = 0.007) and the allele frequencies (A, B) (p = 0.003)
distribution of attempted suicide patients with SCZ was found to
be significantly different from the non-attempted SCZ patients.
The percentage of the genotypes with mutation allele (AB/BB)
and mutation allele (B) was found to be statistically higher in the
attempted suicide SCZ patients than non-attempted SCZ patients
(Table 3). Again when the MBL2 (AA, AB, BB) genotype, combined
genotype (AA, AB/BB) and the allele frequencies (A, B) of attempted
suicide patients with SCZ were compared with the control group,
the MBL2 (AA, AB, BB) genotype (p = 0.012) distribution of
attempted suicide patients with SCZ was found to be significantly
different from the control group (Table 4). When the MIF (GG, GC,
CC) genotype, combined genotype (grouping by considering the
presence of mutation allele) (GG, GC/CC) (homozygosis normal,
heterozygosis/homozygosis mutant) and the allele frequencies
(G, C) of attempted suicide patients with SCZ were compared with
the non-attempted SCZ patients or the control group, there wasn’t
found to be significantly difference between the groups (p > 0.05)
(Data not shown).
When the MIF (GG, GC, CC) genotype, combined genotype (GG,
GC/CC) and the allele frequencies (G, C) of attempted suicide
Please cite this article as: H. M. Aytac, Y. Oyaci, M. S. Yazar et al., Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients
diagnosed with schizophrenia or bipolar disorder, Journal of Clinical Neuroscience, https://doi.org/10.1016/j.jocn.2020.04.001
3
H.M. Aytac et al. / Journal of Clinical Neuroscience xxx (xxxx) xxx
Table 1
Sociodemographic Characteristics and Suicidal Behavior of Patients.
Schizophrenia (N:108)
Age
Sex
Female
Male
No
Yes
Poisoning
Jumping from a height
Cutting or piercing
Hanging
Violent
Non-violent
Suicid Attempt
Method of Suicide
Type of Suicide
Bipolar Disorder (N:100)
Mean ± SD
Mean ± SD
41.11 ± 10.24
41.45 ± 11.54
N
%
N
%
27
81
73
35
22
9
3
1
91
27
25
75
67.6
32.4
62.8
25.7
8.6
2.8
77.1
22.9
60
40
70
30
17
9
4
0
13
17
60
40
70
30
56.6
30
13.3
0
43.3
56.6
(Abbreviations: SD, standard deviation).
Table 2
The Scale Scores of Patients.
Schizophrenia
PANSS pos.
PANSS neg.
PANSS psycho.
PANSS total
Mean ± SD
11.61 ± 3.80
16.37 ± 5.25
30.07 ± 7.31
58.09 ± 12.98
Bipolar Disorder
HAM-D
YMRS
Mean ± SD
15.02 ± 9.18
8.83 ± 10.39
(Abbreviations: SD, standard deviation; PANSS, positive and
negative syndrome scale; HAM-D, hamilton depression rating scale; YMRS, young mania rating scale; pos., positive;
neg., negative; psycho., psychopathology).
Table 3
Comparison of MBL2 Genotype Distribution of Attempted Suicide Patients Diagnosed
with Schizophrenia to Non-attempted Schizophrenia Patients.
Schizophrenia
Attempted Suicide
MBL2
no
yes
p*
AA
AB
BB
64(%87.7)
6(%8.2)
3(%4.1)
23(%65.7)
8(%22.9)
4(%11.4)
MBL2 (combined)
AA
AB/BB
64 (%87.7)
9 (%12.3)
23(%65.7)
12(%34.3)
0.007
MBL2 (allele)
A
B
134 (%91.8)
12 (%8.2)
54(%77.1)
16(%22.9)
0.003
0.026
4. Discussion
* Pearson chi-square.
Table 4
Comparison of MBL2 Genotype Distribution of Attempted Suicide Patients Diagnosed
with Schizophrenia to the Control Group.
Genotype
MBL2
AA
AB
BB
MBL2 (combined)
AA
AB/BB
MBL2 (allele)
A
B
* Pearson chi-square.
patients with BD were compared with the non-attempted BD
patients, the MIF (GG, GC, CC) genotype (p = 0.038), (GG, GC/CC)
combined genotype (p = 0.011) and the allele frequencies (G, C)
(p = 0.006) distribution of attempted suicide patients with BD were
found to be significantly different from the non-attempted BD
patients. The percentage of the GC genotype and C allele was found
to be statistically higher in the non-attempted BD patients compared to the BD with attempted suicide (Table 5). Again when
the MIF (GG, GC, CC) genotype, combined genotype (GG, GC/CC)
and the allele frequencies (G, C) of attempted suicide patients with
BD were compared with the control group, the MIF (GG, GC, CC)
genotype (p = 0.013), (GG, GC/CC) combined genotype (p = 0.003)
and the allele frequencies (G, C) (p = 0.004) distribution of
attempted suicide patients with BD was found to be significantly
different from the control group. The percentage of the genotypes
with mutation allele (GC/CC) and mutation allele (C) was found to
be statistically higher in the control group compared to the BD
with attempted suicide. (Table 6). When the MBL2 (AA, AB, BB)
genotype, combined genotype (AA, AB/BB) and the allele frequencies (A, B) of attempted suicide patients with BD were compared
with the non-attempted BD patients or the control group, there
wasn’t found to be significantly difference between the genotype
distribution of the groups (p > 0.05) (Data not shown).
p*
Control Group
Attempted Suicide
64(%64)
35(%35)
1(%1)
23(%65.7)
8(%22.9)
4(%11.4)
64 (%64)
36 (%36)
23(%65.7)
12(%34.3)
0.855
163 (%81.5)
37 (%18.5)
54(%77.1)
16(%22.9)
0.430
0.012
Suicide is a major cause of death among patients with SCZ and
the lifetime prevalence of suicide in patients with SCZ has been
estimated to be ten times higher than among the general population [24]. Although no study was found in the literature that examined the relationship between MIF gene or MBL2 gene and SB in
SCZ, Okazaki et al. reported that the MIF gene polymorphisms
are associated with the risk for SCZ especially in adolescent
females, and are potential stratification markers of SCZ [12]. Again,
Foldager et al. found that the genotype ratio with the mutation
allele was higher in this group compared to the healthy control
group in the study about the association between MBL2 and SCZ
[25]. In our study, while the distributions of the MBL2 genotype
of attempted suicide patients in SCZ were statistically significantly
different from the non-attempted SCZ patients, the distributions of
MIF genotype of attempted suicide patients in SCZ weren’t statistically significantly different from the non-attempted SCZ patients.
In literature, genetic predisposition has been shown to contribute
to the multifactorial risk model of SB in SCZ. Most of the studies
have focused on genes involved in the serotonergic pathway. These
studies have reported an association between variants in the serotonin transporter and TPH1 genes [24]. Hu et. al reported that
Please cite this article as: H. M. Aytac, Y. Oyaci, M. S. Yazar et al., Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients
diagnosed with schizophrenia or bipolar disorder, Journal of Clinical Neuroscience, https://doi.org/10.1016/j.jocn.2020.04.001
4
H.M. Aytac et al. / Journal of Clinical Neuroscience xxx (xxxx) xxx
Table 5
Comparison of MIF Genotype Distribution of Attempted Suicide Patients Diagnosed
with the Bipolar Disorder to the Non-attempted Bipolar Disorder Patients.
Bipolar Disorder
Attempted Suicide
MIF
no
yes
p*
GG
GC
CC
49(%70)
19(%27.1)
2(%2.9)
28(%93.3)
2(%6.7)
0(%0)
MIF (combined)
GG
GC/CC
49 (%70)
21 (%30)
28(%93.3)
2(%6.7)
0.011
MIF (allele)
G
C
115 (%82.1)
25 (%17.9)
58(%96.7)
2(%3.3)
0.006
0.038
* Pearson chi-square.
Table 6
Comparison of MIF Genotype Distribution of Attempted Suicide Patients Diagnosed
with Bipolar Disorder to the Control Group.
Genotype
MIF
Control Group
Attempted Suicide
p*
GG
GC
CC
66(%66)
31(%31)
3(%3)
28(%93.3)
2(%6.7)
0(%0)
MIF (combined)
GG
GC/CC
66 (%66)
34 (%34)
28(%93.3)
2(%6.7)
0.003
MIF (allele)
G
C
163 (%81.5)
37 (%18.5)
58(%96.7)
2(%3.3)
0.004
0.013
* Pearson chi-square.
tyrosine hydroxylase polymorphisms may contribute to the risk of
attempted suicide in SCZ even after accounting for established clinical risk factors and ethnic stratification [26]. Another study about
differences in expression of the dopamine- and cAMP-regulated
neuronal phosphoprotein (DARPP-32) gene, which is involved in
dopamine, and possibly serotonin regulation, between patients
diagnosed with SCZ who died by suicide and due to other causes.
With regard to another frequently analyzed gene, the serotonin
transporter 2A (HTR2A), there seems to be no firm evidence for
an association [24].
It has been published that the MIF gene has a relationship with
the HPA axis. The HPA axis has also been considered as a neurobiological factor related to suicide, nearly a 10-fold higher risk of
completed suicide was found in dexamethasone suppression test
(DST) non-suppressors than in DST suppressors in a depression
[14,27]. In our study the MIF (GG, GC, CC) genotype, (GG, GC/CC)
combined genotype and the allele frequencies (G, C) distribution
of attempted suicide patients with BD was found to be significantly
different from the non-attempted BD patients or control group. The
percentage of MIF genotype (GC) of the BD patients without
attempted suicide was found to be higher than the BD patients
with attempted suicide. The percentage of MIF mutation allele
(C) of the BD group without attempted suicide also was found to
be statistically higher than the BD patients with attempted suicide.
As a result of the literature review, only one study investigating the
relationship between MIF and completed suicide was found. In
contrast our study, Shimmyo et al. reported that the effects of MIF794CATT5–8 microsatellite and MIF-173G/C single-nucleotide polymorphism (SNP) on the MIF gene promoter might not contribute to
the genetic risk of completed suicide in the Japanese population
[14].
Although less is known concerning whether relationships of
inflammatory pathways with suicide may be different from mood
disorders. Only a few studies reported that such relationships exist.
Increased levels of baseline inflammatory markers have been
associated with depression and psychological stress which are
well-determined risk factors for SB [28]. For instance, C-reactive
protein (CRP) levels are higher among the attempted suicide
patients diagnosed with mood disorder [29]. Again it was found
that attempted suicide patients have increased serum levels of soluble IL-2 receptors compared to the control group [30]. Lindqvist
et al. reported increased levels of IL-6 in the CSF of suicide attempters compared to the control group [31]. Janelidze et al. found that
the levels of TNF-a and IL-6 were increased and the levels of IL-2
were decreased in patients who attempted suicide [32].
In our study, no significant difference was found between
attempted suicide BD and non-attempted groups according to
the variant of MBL2 which is involved in an innate immune
response. In another study on the role of the innate immune system in attempted suicide, Pandey et al. reported that the protein
expression of toll-like receptors-2 (TLR2), TLR3, TLR4, TLR6 and
TLR10, and mRNA expression of TLR2 and TLR3 was significantly
increased in the depressed suicide group compared with control
group contrary to our study [33]. When other studies on SB in literature are reviewed, It was reported that violent SB in BD is associated with nitric oxide synthase 3 gene polymorphism [5].
Benedetti et al. also published a significant effect of Circadian Locomotor Output Cycles Kaput (CLOCK) gene variants and exposure to
early stress on hopelessness and suicide in patients diagnosed with
bipolar depression [34]. It was detected an association between
suicide attempts and the inter-alpha-trypsin inhibitor heavy chain
3/4 (ITIH3/4) region in a combined group of patients with BD, SCZ
and related psychosis spectrum disorders [35]. When the genetic
association analyses examining polymorphisms within BDNF,
COMT, cyclic AMP-responsive element-binding protein 1 (CREB1)
and mitogen-activated protein kinase 1 (MAPK1) genes were performed in 259 bipolar patients according to suicide attempt, the
significant associations were found with variations in rs13515
(MAPK1) and rs6740584 (CREB1) polymorphisms. No associations
were found with polymorphisms within COMT and BDNF genes
[6].
If the limitations of our study should be considered, MIF-173G/
C single-nucleotide variants were examined, but it was not possible to know the other functional MIF-794CATT5–8 microsatellite
variant of SCZ or BD with attempted suicide. Also, in our study,
MBL2 gene polymorphism in codon 54 was examined, but it was
not possible to know whether other polymorphisms which may
disrupt MBL2 structure and prevent trimerization (mutations in
codon 52 and codon 57) contributed to attempted suicide in SCZ
or BD.
As a conclusion, we found that while the MBL2 gene variant
may be associated with attempted suicide in patients diagnosed
with SCZ, the MIF gene variant may be related to attempted suicide
in BD patients. Confirmation of these findings with other gene variants in different ethnic populations may provide a better understanding of the relationship between MIF or MBL2 gene variants
and attempted suicide in SCZ or BD.
Acknowledgements
We would like to thank all patients and healthy controls for
their willingness to participate in the present study.
Statement of interest
All authors declare not to have any conflicts of interest that
might be interpreted as influencing the content of the manuscript.
Please cite this article as: H. M. Aytac, Y. Oyaci, M. S. Yazar et al., Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients
diagnosed with schizophrenia or bipolar disorder, Journal of Clinical Neuroscience, https://doi.org/10.1016/j.jocn.2020.04.001
H.M. Aytac et al. / Journal of Clinical Neuroscience xxx (xxxx) xxx
Funding
The authors received no specific funding for this work.
Contributions of authors
HMA and SP are responsible for the formulation of overarching
research goals and aims, integrity of the data and accuracy of data
analyses. HMA, YO, MSY, AE, and SP conceived and designed the
study. SP, YO and AE are the responsible provisions of study materials and laboratory samples. All authors acquired, analyzed, and
interpreted all data. HMA drafted the manuscript. All authors critically revised the manuscript. SP and MSY supervised the study.
Ethical Standards
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and
institutional committees on human experimentation and with
the Helsinki Declaration of 1975, as revised in 2008 [36].
References
[1] Aydın N, Aytaç HM, Yazıcı E, Yılmaz D, Çetinay Aydın P, Yüksel Yalçın G, et al.
Rediscovery of penicillin of psychiatry: haloperidol decanoate. Psychiatry
Clinical Psychopharmacol 2019;29:264–75.
[2] Fuller-Thomson E, Hollister B. Schizophrenia and suicide attempts: findings
from a representative community-based canadian sample. Schizophr Res
Treatment 2016;2016:3165243.
[3] Berkol TD, Balcıoğlu YH, Aytaç HM, Kırlıoğlu SS, Islam S, Ozyıldırım I.
Maintenance treatment trends, therapeutic outcomes and their association
with clinical features in remitted bipolar disorder. J Neurobehav Sci
2017;4:99–105.
[4] Tidemalm D, Haglund A, Karanti A, Landén M, Runeson B. Attempted suicide in
bipolar disorder: risk factors in a cohort of 6086 patients. PLoS ONE 2014;9:
e94097.
[5] Oliveira J, Debnath M, Etain B, Bennabi M, Hamdani N, Lajnef M, et al. Violent
suicidal behaviour in bipolar disorder is associated with nitric oxide synthase 3
gene polymorphism. Acta Psychiatr Scand 2015;132:218–25.
[6] Antypa N, Souery D, Tomasini M, Albani D, Fusco F, Mendlewicz J, et al. Clinical
and genetic factors associated with suicide in mood disorder patients. Eur Arch
Psychiatry Clin Neurosci 2016;266:181–93.
[7] Mirkovic B, Laurent C, Podlipski M-A, Frebourg T, Cohen D, Gerardin P. Genetic
association studies of suicidal behavior: a review of the past 10 years, progress,
limitations, and future directions. Front Psychiatry 2016;7:158.
[8] Brundin L, Bryleva EY, Rajamani KT. Role of inflammation in suicide: from
mechanisms to treatment. Neuropsychopharmacology 2017;42:271.
[9] Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, et al.
Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims.
J Psychiatr Res 2012;46:57–63.
[10] Xu L, Li Y, Sun H, Zhen X, Qiao C, Tian S, et al. Current developments of
macrophage migration inhibitory factor (MIF) inhibitors. Drug Discovery
Today 2013;18:592–600.
[11] Bloom J, Al-Abed Y. MIF: mood improving/inhibiting factor?. J
Neuroinflammation 2014;11:11.
[12] Okazaki S, Hishimoto A, Otsuka I, Watanabe Y, Numata S, Boku S, et al.
Increased serum levels and promoter polymorphisms of macrophage
migration inhibitory factor in schizophrenia. Prog Neuro-Psychopharmacol
Biol Psychiatry 2018;83:33–41.
5
[13] Gadjeva M, Takahashi K, Thiel S. Mannan-binding lectin—a soluble pattern
recognition molecule. Mol Immunol 2004;41:113–21.
[14] Shimmyo N, Hishimoto A, Otsuka I, Okazaki S, Boku S, Mouri K, et al.
association study of MIF promoter polymorphisms with suicide completers in
the Japanese population. Neuropsychiatr Dis Treat 2017;13:899.
[15] First MB, Spitzer RL, Gibbon M, Williams JB. User’s guide for the Structured
clinical interview for DSM-IV axis I disorders SCID-I: clinician version.
American Psychiatric Pub 1997.
[16] Çorapçıoğlu A, Aydemir Ö, Yıldız M, Esen A, Köroğlu E. DSM-IV Eksen I
Bozuklukları (SCID-I) için yapılandırılmısß klinik görüsßme, klinik
versiyon. Ankara: Hekimler yayın birliği; 1999.
[17] Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability,
validity and sensitivity. British J Psychiatry 1978;133:429–35.
[18] Karadağ F, Oral ET, Aran Yalçın F, Erten E. Young mani derecelendirme ölçeg
˘inin Türkiye’de geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi
2001;13:107–14.
[19] Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry
1960;23:56–62.
_ Türkçapar H, Is
_ßcan N, Özbay H. Hamilton Depresyon
[20] Akdemir A, Örsel S, Dağ I,
Derecelendirme Ölçeği (HDDÖ)’nin geçerliği, güvenirliği ve klinikte kullanımı.
Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996;4:251–9.
[21] Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
[22] Kostakoğlu A, Batur S, Tiryaki A, Göğüsß A. Pozitif ve negatif sendrom ölçeğinin
(PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi
1999;14:23–32.
[23] Eksßi F, Pehlivan S, Erdoğan MB, Bayram A, Oğuzkan-Balcı S, Yamak B, et al.
MBL2 and MIF gene polymorphisms in cardiovascular patients with
atherosclerotic lesions undergoing heart valve replacement. Biotechnol
Biotechnol Equip 2017;31:1173–7.
[24] Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P. Suicide in
schizophrenia. Expert Rev Neurother 2010;10:1153–64.
[25] Foldager L, Steffensen R, Thiel S, Als TD, Nielsen HJ, Nordentoft M, et al. MBL
and MASP-2 concentrations in serum and MBL2 promoter polymorphisms are
associated to schizophrenia. Acta Neuropsychiatr 2012;24:199–207.
[26] Hu J, Chan LF, Souza RP, Tampakeras M, Kennedy JL, Zai C, et al. The role of
tyrosine hydroxylase gene variants in suicide attempt in schizophrenia.
Neurosci Lett 2014;559:39–43.
[27] Coryell W, Schlesser M. The dexamethasone suppression test and suicide
prediction. Am J Psychiatry 2001;158:748–53.
[28] Batty GD, Jung KJ, Lee S, Back JH, Jee SH. Systemic inflammation and suicide
risk: cohort study of 419 527 Korean men and women. J Epidemiol Community
Health 2018;72:572–4.
[29] Loas G, Dalleau E, Lecointe H, Yon V. Relationships between anhedonia,
alexithymia, impulsivity, suicidal ideation, recent suicide attempt, C-reactive
protein and serum lipid levels among 122 inpatients with mood or anxious
disorders. Psychiatry Res 2016;246:296–302.
[30] Nässberger L, Träskman-Bendz L. Increased soluble interleukin-2 receptor
concentrations in suicide attempters. Acta Psychiatr Scand 1993;88:48–52.
[31] Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al.
Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and
related to symptom severity. Biol Psychiatry 2009;66:287–92.
[32] Janelidze S, Mattei D, Westrin Å, Träskman-Bendz L, Brundin L. Cytokine levels
in the blood may distinguish suicide attempters from depressed patients.
Brain Behav Immun 2011;25:335–9.
[33] Pandey GN, Rizavi HS, Bhaumik R, Ren X. Innate immunity in the postmortem
brain of depressed and suicide subjects: role of toll-like receptors. Brain Behav
Immun 2019;75:101–11.
[34] Benedetti F, Riccaboni R, Dallaspezia S, Locatelli C, Smeraldi E, Colombo C.
Effects of CLOCK gene variants and early stress on hopelessness and suicide in
bipolar depression. Chronobiol Int 2015;32:1156–61.
[35] Finseth PI, Sønderby IE, Djurovic S, Agartz I, Malt UF, Melle I, et al. Association
analysis between suicidal behaviour and candidate genes of bipolar disorder
and schizophrenia. J Affect Disord 2014;163:110–4.
[36] Williams JR. The Declaration of Helsinki and public health. Bull World Health
Organ 2008;86:650–2.
Please cite this article as: H. M. Aytac, Y. Oyaci, M. S. Yazar et al., Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients
diagnosed with schizophrenia or bipolar disorder, Journal of Clinical Neuroscience, https://doi.org/10.1016/j.jocn.2020.04.001